CA 27.29 BREAST CANCER MARKER Test
Components: Price 1360.0 AED
Sample Condition: 2 mL (0.5 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history. Duly filled Test Send Out Consent Form is mandatory.
Report Delivery: Sample by 7th of the month; Report after 2-3 weeks
Method: Immunoassay
Test Type: Cancer
Doctor: Oncologist, Gynecologist
Test Department: OS
Pre Test Information: Provide brief clinical history. Duly filled Test Send Out Consent Form is mandatory.
Test Details
The CA 27.29 breast cancer marker test is a blood test that measures the level of a protein called CA 27.29 in the blood. CA 27.29 is a tumor marker that is often elevated in people with breast cancer, particularly those with advanced or metastatic disease.
The test is primarily used to monitor the response to treatment and detect any recurrence of breast cancer. It is not typically used as a screening test for the general population or to diagnose breast cancer on its own. Instead, it is used in conjunction with other diagnostic tests, such as mammograms, biopsies, and imaging scans.
The CA 27.29 test is most useful for individuals who have been diagnosed with breast cancer and are undergoing treatment or surveillance. By monitoring the levels of CA 27.29 over time, doctors can assess the effectiveness of treatment and detect any signs of cancer recurrence at an earlier stage.
It is important to note that while elevated levels of CA 27.29 can indicate the presence of breast cancer, they can also be elevated in other conditions, such as benign breast disease, liver disease, and certain types of ovarian and lung cancer. Therefore, the test should be interpreted in conjunction with other clinical findings and diagnostic tests.
Overall, the CA 27.29 breast cancer marker test is a valuable tool in the management of breast cancer patients, helping to guide treatment decisions and monitor disease progression.
| Test Name | CA 27.29 BREAST CANCER MARKER Test |
|---|---|
| Components | |
| Price | 1360.0 AED |
| Sample Condition | 2 mL (0.5 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history. Duly filled Test Send Out Consent Formis mandatory. |
| Report Delivery | Sample by 7th of the month; Report after 2??3 weeks |
| Method | Immunoassay |
| Test type | Cancer |
| Doctor | Oncologist, Gynecologist |
| Test Department: | OS |
| Pre Test Information | Provide brief clinical history. Duly filled Test Send Out Consent Formis mandatory. |
| Test Details |
The CA 27.29 breast cancer marker test is a blood test that measures the level of a protein called CA 27.29 in the blood. CA 27.29 is a tumor marker that is often elevated in people with breast cancer, particularly those with advanced or metastatic disease. The test is primarily used to monitor the response to treatment and detect any recurrence of breast cancer. It is not typically used as a screening test for the general population or to diagnose breast cancer on its own. Instead, it is used in conjunction with other diagnostic tests, such as mammograms, biopsies, and imaging scans. The CA 27.29 test is most useful for individuals who have been diagnosed with breast cancer and are undergoing treatment or surveillance. By monitoring the levels of CA 27.29 over time, doctors can assess the effectiveness of treatment and detect any signs of cancer recurrence at an earlier stage. It is important to note that while elevated levels of CA 27.29 can indicate the presence of breast cancer, they can also be elevated in other conditions, such as benign breast disease, liver disease, and certain types of ovarian and lung cancer. Therefore, the test should be interpreted in conjunction with other clinical findings and diagnostic tests. Overall, the CA 27.29 breast cancer marker test is a valuable tool in the management of breast cancer patients, helping to guide treatment decisions and monitor disease progression. |
